Modified Delphi Study on Oral Mucositis/Stomatitis Prevention and Management in Patients Receiving Datopotamab Deruxtecan

dc.contributor.authorBossi, Paolo
dc.contributor.authorAtmaca, Akin
dc.contributor.authorBachelot, Thomas
dc.contributor.authorBartsch, Rupert
dc.contributor.authorBianchini, Giampaolo
dc.contributor.authorChu, Quincy
dc.contributor.authorCornelissen, Robin
dc.contributor.authorFelip, Enriqueta
dc.contributor.authorGirard, Nicolas
dc.contributor.authorPassiglia, Francesco
dc.contributor.authorPernas, Sònia
dc.contributor.authorPhillips, Melissa
dc.contributor.authorPlanchard, David
dc.contributor.authorZamagni, Claudio
dc.contributor.authorClark, Jo
dc.contributor.authorMatthews, Cecile
dc.contributor.authorGoerke, Lutz
dc.contributor.authorPistilli, Barbara
dc.date.accessioned2026-07-03T11:20:46Z
dc.date.available2026-07-03T11:20:46Z
dc.date.issued2026-01-01
dc.date.updated2026-05-21T12:43:11Z
dc.description.abstractBackgroundOral mucositis/stomatitis is a common adverse event during cancer treatment that can disrupt oral functioning and adherence to treatment. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, has shown promise in treating solid tumors. It has been associated with oral mucositis/stomatitis in clinical trials for breast and lung cancer (TROPION program). Currently, there is a lack of formalized guidelines for managing Dato-DXd-associated oral mucositis/stomatitis. The present study employed a modified Delphi approach to establish expert consensus on preventing, diagnosing, monitoring, and treating oral mucositis/stomatitis secondary to Dato-DXd and to improve patient care and clinical outcomes.Materials and MethodsA four-stage modified Delphi study engaging 15 oncology experts from Europe and Canada was used to establish consensus on managing Dato-DXd-induced oral mucositis/stomatitis in lung and breast cancer patients. Experts were selected based on their roles as investigators in Dato-DXd clinical trials, including but not limited to TROPION-PanTumor01, TROPION-Lung01, TROPION-Lung05, and TROPION-Breast01, and their experience managing cancer treatment-associated oral mucositis/stomatitis. The Delphi process included an initial meeting, two anonymized surveys, an in-person consensus meeting, and virtual one-to-one sessions for absentees.ResultsExpert consensus was reached on recommendations for managing Dato-DXd-associated oral mucositis/stomatitis, and experts highlighted the importance of establishing guidance to improve patient quality of life and clinical outcomes. Key recommendations included prophylactic dexamethasone mouthwash, patient education, and behavioral changes. Early detection through self-checks and monitoring was emphasized, and recommended treatment strategies were tailored to oral mucositis/stomatitis severity. Treatment recommendations included dose modifications and discontinuation for severe cases.ConclusionsThis study offers expert guidance on managing Dato-DXd-associated oral mucositis/stomatitis, filling a crucial gap in patient care. Ongoing efforts to generate Dato-DXd-specific data will facilitate the creation of standardized, evidence-based protocols to improve patient safety and treatment outcomes.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1365-2354
dc.identifier.urihttps://hdl.handle.net/2445/230419
dc.language.isoeng
dc.publisherJohn Wiley & Sons
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1155/ecc/6518713
dc.relation.ispartofEuropean Journal of Cancer Care, 2026, vol. 2026, num.. 1
dc.relation.urihttps://doi.org/10.1155/ecc/6518713
dc.rightscc by (c) Bossi, Paolo et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMalalts de càncer
dc.subject.classificationEducació dels pacients
dc.subject.otherCancer patients
dc.subject.otherPatient education
dc.titleModified Delphi Study on Oral Mucositis/Stomatitis Prevention and Management in Patients Receiving Datopotamab Deruxtecan
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
European Journal of Cancer Care - 2026 - Bossi - Modified Delphi Study on Oral Mucositis Stomatitis Prevention and.pdf
Mida:
546.23 KB
Format:
Adobe Portable Document Format